Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ko Yamamoto

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
JACC. Cardiovascular Interventions|May 15, 2024
An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary InterventionKo Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
Journal of the American Heart Association|July 26, 2024
Aspirin-Free Strategy for Percutaneous Coronary Intervention in Patients With Oral Anticoagulation: Prespecified Subgroup Analysis From the STOPDAPT-3 TrialMasahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Journal of the American Heart Association|September 17, 2021
Newly Diagnosed Atrial Fibrillation in Acute Myocardial InfarctionYuki Obayashi, Hiroki Shiomi, Takeshi Morimoto, et al.
Circulation. Cardiovascular Interventions|May 14, 2025
Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 TrialTetsuya Ishikawa, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
Circulation Reports|June 11, 2025
An Aspirin-Free Strategy for Patients Undergoing Staged Percutaneous Coronary Intervention　- A Subgroup Analysis of the STOPDAPT-3 TrialKo Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
Circulation. Cardiovascular Interventions|September 24, 2025
Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral AnticoagulationMasahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 24, 2024
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trialKo Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 3, 2023
Biodegradable or durable polymer drug-eluting stents in patients with coronary artery disease: ten-year outcomes of the randomised NEXT TrialMasahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
JACC. Asia|November 7, 2022
Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting StentsYusuke Yoshikawa, Hiroki Shiomi, Takeshi Morimoto, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 8, 2022
Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome　- A Post Hoc Secondary Analysis of STOPDAPT-2 ACSHirotoshi Watanabe, Takeshi Morimoto, Ko Yamamoto, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
JACC. Cardiovascular Interventions|May 15, 2024
An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary InterventionKo Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
Journal of the American Heart Association|July 26, 2024
Aspirin-Free Strategy for Percutaneous Coronary Intervention in Patients With Oral Anticoagulation: Prespecified Subgroup Analysis From the STOPDAPT-3 TrialMasahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Journal of the American Heart Association|September 17, 2021
Newly Diagnosed Atrial Fibrillation in Acute Myocardial InfarctionYuki Obayashi, Hiroki Shiomi, Takeshi Morimoto, et al.
Circulation. Cardiovascular Interventions|May 14, 2025
Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 TrialTetsuya Ishikawa, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
Circulation Reports|June 11, 2025
An Aspirin-Free Strategy for Patients Undergoing Staged Percutaneous Coronary Intervention　- A Subgroup Analysis of the STOPDAPT-3 TrialKo Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
Circulation. Cardiovascular Interventions|September 24, 2025
Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral AnticoagulationMasahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 24, 2024
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trialKo Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 3, 2023
Biodegradable or durable polymer drug-eluting stents in patients with coronary artery disease: ten-year outcomes of the randomised NEXT TrialMasahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
JACC. Asia|November 7, 2022
Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting StentsYusuke Yoshikawa, Hiroki Shiomi, Takeshi Morimoto, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 8, 2022
Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome　- A Post Hoc Secondary Analysis of STOPDAPT-2 ACSHirotoshi Watanabe, Takeshi Morimoto, Ko Yamamoto, et al.
Pageof 10